Monday, 18 March 2019
Latest news
Main » Excalibur Management Corp Trims Stake in Johnson & Johnson (NYSE:JNJ)

Excalibur Management Corp Trims Stake in Johnson & Johnson (NYSE:JNJ)

17 April 2018

35 investors sold all, 884 reduced holdings as JNJ ratio improved. 143 funds opened positions while 654 raised stakes. Eqis Capital holds 0.2% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 27,787 shares.

The healthcare conglomerate, whose stock had climbed about 3 percent over the previous six days, reported better-than-expected profit in the first quarter, helped by strong demand for its cancer treatments. Top seller Remicade, for rheumatoid arthritis, ulcerative colitis and other immune disorders, saw sales fall 17 percent to $1.39 billion, hurt by recent competition in the U.S. But J&J's other drugs for immune disorders, Simponi and Stelara, compensated with sales jumps of more than 20 percent each, to a combined $1.58 billion.

Perella Weinberg Prtnrs Mgmt L P reported 0.77% in Johnson & Johnson (NYSE:JNJ). It dived, as 72 investors sold BMY shares while 526 reduced holdings. Fukoku Mutual Life Ins Communication holds 0.24% or 11,550 shares. IHT Wealth Management LLC raised its position in shares of Johnson & Johnson by 46.4% during the 2nd quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Mogy Joel R Invest Counsel reported 180,530 shares. Diversified Trust reported 0.37% stake. Osher Van De Voorde Invest Mngmt, a California-based fund reported 62,072 shares.

Excluding $1 billion in write-downs on the value of assets and $300 million in other one-time charges, adjusted income came to $5.64 billion, or $2.06, a nickel better than expected. Company insiders own 0.22% of the company's stock.

In Johnsn&Johnsn (JNJ) was rose the holdings owned by Adell Harriman & Carpenter Inc. Stifel Financial Corp now owns 2,572,663 shares of the company's stock valued at $334,777,000 after buying an additional 2,534,918 shares during the last quarter. Jp Marvel Advisors Ltd Liability Corporation owns 3.15% invested in Johnson & Johnson (NYSE:JNJ) for 74,031 shares. The stock increased 0.87% or $1.14 during the last trading session, reaching $131.76. About 6.38M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 1.12% since April 17, 2017 and is uptrending. The stock underperformed the S&P 500 by 10.43%.

Sit Investment Associates Inc, which manages about $6.54 billion and $4.19 billion US Long portfolio, upped its stake in Gilead Sciences Inc (NASDAQ:GILD) by 213,710 shares to 271,860 shares, valued at $19.48M in 2017Q4, according to the filing. Five analysts have rated the stock with a sell rating, nine have given a hold rating and eight have assigned a buy rating to the stock. 50% are bullish. With $170.0 highest and $110.0 lowest [Target] Johnson \u0026 Johnson has $148.73 average [Target] or 12.88% above the current ($131.76) price. Since October 18, 2017 according to StockzIntelligence Inc Johnson \u0026 Johnson has 22 analyst reports. Moreover, Orbimed Advsrs Ltd Liability has 0.82% invested in Johnson & Johnson (NYSE:JNJ) for 465,300 shs. RBC Capital Markets maintained the shares of JNJ in report on Wednesday, July 20 with "Outperform" rating. On Tuesday, April 10 the stock rating was maintained by Morgan Stanley with "Equal-Weight". Hollow Brook Wealth Ltd Liability invested 4.46% in Johnson & Johnson (NYSE:JNJ). On Friday, April 13 the rating was maintained by Jefferies with "Buy". Vetr lowered shares of Johnson & Johnson from a "buy" rating to a "hold" rating and set a $147.40 price objective for the a report on Monday, January 8th. Royal Bank of Canada reissued a "buy" rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. The stock has "Buy" rating by Cowen & Co on Friday, October 6. Barclays Capital maintained it with "Overweight" rating and $120 target in Wednesday, April 20 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Excalibur Management Corp Trims Stake in Johnson & Johnson (NYSE:JNJ)